Inotiv (NOTV) Scheduled to Post Earnings on Thursday

Inotiv (NASDAQ:NOTV) will be posting its quarterly earnings results after the market closes on Thursday, August 8th. Analysts expect Inotiv to post earnings of ($0.09) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Inotiv (NASDAQ:NOTV) last announced its earnings results on Wednesday, May 15th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.34). Inotiv had a negative net margin of 12.90% and a negative return on equity of 11.23%. The company had revenue of $119.04 million for the quarter, compared to analyst estimates of $136.74 million. On average, analysts expect Inotiv to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Inotiv Stock Up 0.6 %

Shares of NASDAQ:NOTV opened at $1.70 on Wednesday. Inotiv has a 52-week low of $1.51 and a 52-week high of $11.42. The company has a market capitalization of $44.15 million, a P/E ratio of -0.61 and a beta of 3.34. The stock’s fifty day simple moving average is $1.84 and its 200-day simple moving average is $4.35.

Wall Street Analyst Weigh In

A number of analysts have issued reports on NOTV shares. Jefferies Financial Group lowered Inotiv from a “buy” rating to a “hold” rating and decreased their price target for the stock from $11.50 to $3.75 in a research note on Tuesday, May 14th. Lake Street Capital restated a “hold” rating and issued a $2.00 target price (down from $10.00) on shares of Inotiv in a report on Thursday, May 16th. Finally, Craig Hallum decreased their price target on shares of Inotiv from $25.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, May 16th.

About Inotiv

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.